American Migraine Foundation Highlights HeadaTerm2 in Its Latest Device Recommendations, Backed by Clinical Evidence

VANCOUVER, BC, June 16, 2025 /PRNewswire/ -- WAT Medical Enterprise Ltd. is pleased to announce that its migraine relief device, HeadaTerm 2, is now featured on the American Migraine Foundation's (AMF) updated Device Corner, a patient education resource highlighting FDA-cleared neuromodulation devices for migraine treatment.

HeadaTerm 2 is a non-invasive, drug-free device designed to help manage migraine symptoms through external trigeminal nerve stimulation (eTNS). It delivers mild electrical impulses to the trigeminal nerve region to help regulate pain pathways associated with migraine onset. Its portable, user-friendly design makes it a practical solution for individuals seeking alternatives to pharmaceutical treatments.

HeadaTerm 2's inclusion on the AMF's Device Corner aligns with an increasing body of clinical evidence supporting its use. A randomized controlled trial published in The American Journal of Emergency Medicine (Hokenek et al., 2021) demonstrated a 69.66% reduction in migraine pain among participants using the device, with a lower reliance on rescue medications within two hours of treatment. These findings underscore the potential role of neuromodulation in both acute care settings and at-home use.

FDA-cleared and eligible for FSA/HSA reimbursement, HeadaTerm 2 offers a compelling option for those seeking effective migraine relief without medication-related side effects. As migraine continues to affect over one billion people worldwide, WAT Medical remains committed to developing evidence-based, accessible therapies for neurological conditions.

WAT Medical continues to invest in the research and development of wearable medical technologies that prioritize patient safety, portability, and clinical validation. The company's inclusion in the AMF Device Corner reflects its ongoing mission to expand access to drug-free treatment solutions for migraine and other chronic conditions.

SOURCE WAT Medical Enterprise Ltd.